Esperion Therapeutis.Inc. buy Heureka
Start price
26.02.20
/
50%
€56.00
Target price
09.03.20
€62.00
Performance (%)
-30.14%
End price
09.03.20
€39.12
Summary
This prediction ended on 09.03.20 with a price of €39.12. Massive losses of -30.14% were the result for the BUY prediction by Heureka. Heureka has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Esperion Therapeutis.Inc. | - | - | - | - |
| iShares Core DAX® | -1,11 % | -0,85 % | 2,02 % | 51,34 % |
| iShares Nasdaq 100 | -4,35 % | -5,76 % | 26,25 % | 78,91 % |
| iShares Nikkei 225® | -6,79 % | -10,34 % | 53,21 % | 67,90 % |
| iShares S&P 500 | -1,79 % | -0,33 % | 21,46 % | 65,97 % |
Comments by Heureka for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Buy mit Kursziel 62,0
In the thread Trading Esperion Therapeutis.Inc.
Stopped prediction by Heureka for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
Start price
Target price
Perf. (%)
€52.34
13.01.20
13.01.20
€110.00
10.02.20
10.02.20
15.67%
10.02.20
10.02.20
